Understanding outcomes and risk factors in early-stage bladder cancer

Plain-English translation of NCT05792033 on ClinicalTrials.gov ↗ · Source last updated April 2023 · Translation generated June 2026 · How we translate trials

What is this trial?

This is a research registry — a large database — collecting information from patients across multiple hospitals who have been diagnosed with T1 bladder cancer, which is an early stage of the disease. Researchers want to gather detailed, accurate information about your cancer type, imaging results, and pathology findings to better understand which patients are at higher risk for recurrence or progression.

Doctors currently struggle to predict outcomes accurately for early-stage bladder cancer patients because tissue samples are often damaged during standard surgery, leading to inconsistent diagnoses. By collecting organized, prospective data from multiple centers and having expert specialists review pathology slides, researchers hope to develop a better risk assessment tool to guide treatment decisions.

Do you qualify?

You likely qualify if…

you have been diagnosed with primary T1 bladder cancer confirmed by pathology
you have had a second follow-up surgery (called 2nd look TURB) that confirms T1 disease
imaging scans show no spread to lymph nodes or distant organs
you are willing to undergo standard surgical treatment and follow-up care as recommended by current guidelines
if cancer persists after the second surgery, the pathology sample must contain detrusor muscle (the bladder wall muscle)

You likely don't qualify if…

you have a history of previous bladder cancer
your cancer was found to have progressed to muscle-invasive bladder cancer at the second surgery
you have conditions that make surgery too risky, such as severe bladder scarring or poor overall health
you have a life expectancy of less than one year
you have had or currently have cancer in your upper urinary tract (ureters or kidneys)

What participation looks like

As a participant, you would allow researchers to collect and review your medical records, pathology reports, and imaging results related to your bladder cancer diagnosis and treatment. You would receive standard surgical care and follow-up treatment according to current guidelines at your hospital, while researchers gather data on how you respond to treatment over time. The study aims to enroll 700 patients across multiple centers to build a comprehensive database that will help doctors better understand bladder cancer outcomes.

AI-generated summary from trial data · Jun 10, 2026 · Not medical advice

Trial locations(1 site)

Austria

Medical University of Vienna, Vienna

Key details

Sponsor

Medical University of Vienna

Collaborators

University of Turin, Italy

Enrollment target

~700 participants

Started

June 2021

Primary completion

December 2023

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years – 90 Years

Last updated on clinicaltrials.gov in April 2023.

Contact the research team directly

Reach out to the team running this trial. Response times vary — some teams are faster than others.

Central contact

David D'Andrea, MD

Medical University of Vienna

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.

View full record on ClinicalTrials.gov